Cyclerion Therapeutics, Inc. announced on October 17, 2023, the company and Anjeza Gjino, Chief Financial Officer, entered into a Separation and Release of Claims Agreement, dated such date, pursuant to which Ms. Gjino will resign from Cyclerion. Ms. Gjino?s resignation is not due to any disagreement with Cyclerion on any matter relating to Cyclerion operations, policies or practices. Under the Agreement, Ms. Gjino?s resignation will be effective the second business day after Cyclerion?s filing with the Securities and Exchange Commission of its Form 10-Q for the quarter ended September 30, 2023.

Ms. Gjino has agreed to postpone her resignation in order to assist Cyclerion with an orderly transition of her responsibilities and to assist in the completion of the Form 10-Q.